Daxor (NASDAQ:DXR) Trading Down 1.2% - Should You Sell?
Daxor Corporation (NASDAQ:DXR) shares fell 1.2% during mid-day trading on Wednesday, with the stock trading as low as $12.60. Trading volume was significantly lower than average. Analysts have given the stock a Moderate Buy rating with a target price of $25.00. Institutional investors own 1.34% of the company's stock. Daxor specializes in blood volume measurement technology. Despite the recent dip, analysts suggest considering other stocks for better investment opportunities.
Daxor Corporation (NASDAQ:DXR - Get Free Report) traded down 1.2% during mid-day trading on Wednesday . The stock traded as low as $12.60 and last traded at $12.79. 888 shares were traded during trading, a decline of 93% from the average session volume of 12,613 shares. The stock had previously closed at $12.94.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a "hold (c-)" rating on shares of Daxor in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $25.00.
Get Our Latest Stock Analysis on DXR
Daxor Price Performance
The business has a 50-day moving average price of $12.78 and a two-hundred day moving average price of $10.60.
Institutional Trading of Daxor
An institutional investor recently bought a new position in Daxor stock. Osaic Holdings Inc. acquired a new position in shares of Daxor Corporation (NASDAQ:DXR - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 8,750 shares of the company's stock, valued at approximately $86,000. Osaic Holdings Inc. owned approximately 0.18% of Daxor at the end of the most recent reporting period. Institutional investors and hedge funds own 1.34% of the company's stock.
About Daxor
(Get Free Report)Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.
Featured Articles
- Five stocks we like better than Daxor
- When to Sell a Stock for Profit or Loss
- onsemi Places a $6 Billion Bet on Its Own Stock
- Stock Analyst Ratings and Canadian Analyst Ratings
- HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
- What Are the U.K. Market Holidays? How to Invest and Trade
- End the Year Strong With These 3 Comeback Champions
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Daxor Right Now?
Before you consider Daxor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Daxor wasn't on the list.
While Daxor currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
